Financial reports
10-Q
2023 Q1
Quarterly report
29 Jun 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
13 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
8 Nov 21
10-Q
2021 Q2
Quarterly report
9 Aug 21
Current reports
8-K
Departure of Directors or Certain Officers
16 Aug 23
8-K
Departure of Directors or Certain Officers
21 Jul 23
8-K
Other Events
11 Jul 23
8-K
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
30 May 23
8-K
Cost Associated with Exit or Disposal Activities
4 May 23
8-K
Departure of Directors or Certain Officers
30 Mar 23
8-K
Aceragen ANNOUNCES Recommendation of DaTA monitoring COMMITTEE in TERRA Study
6 Feb 23
8-K
Entry into a Material Definitive Agreement
3 Feb 23
8-K
Regulation FD Disclosure
18 Jan 23
8-K
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
17 Jan 23
Registration and prospectus
15-12G
Securities registration termination
28 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Aug 23
POS AM
Prospectus update (post-effective amendment)
16 Aug 23
POS AM
Prospectus update (post-effective amendment)
16 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Aug 23
POS AM
Prospectus update (post-effective amendment)
16 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Aug 23
POS AM
Prospectus update (post-effective amendment)
16 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Aug 23
Proxies
DEF 14A
Definitive proxy
21 Jul 23
PRE 14A
Preliminary proxy
11 Jul 23
DEFA14A
Additional proxy soliciting materials
11 Jul 23
DEF 14A
Definitive proxy
8 Dec 22
PRE 14A
Preliminary proxy
18 Nov 22
DEFA14A
Additional proxy soliciting materials
30 Sep 22
DEFA14A
Additional proxy soliciting materials
28 Sep 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
Other
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
Ownership
4
MAXINE GOWEN
11 Aug 23
4
VINCENT MILANO
11 Aug 23
144
Notice of proposed sale of securities
10 Aug 23
144
Notice of proposed sale of securities
10 Aug 23
SC 13D/A
Pillar Pharmaceuticals 6, L.P.
3 Aug 23
144
Notice of proposed sale of securities
25 Jul 23
4
YOUSSEF EL ZEIN
19 Jul 23
4
YOUSSEF EL ZEIN
19 Jul 23
3/A
YOUSSEF EL ZEIN
19 Jul 23
SC 13D/A
Pillar Pharmaceuticals 6, L.P.
17 Jul 23